Windtree Therapeutics, Inc. Cash and Short Term Investments

Cash and Short Term Investments of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cash and Short Term Investments growth rates and interactive chart. Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities. Cash and short term investments are considered very liquid assets.


Highlights and Quick Summary

  • Cash and Short Term Investments for the quarter ending June 29, 2020 was $31.5 Million (a 87.6% increase compared to previous quarter)
  • Year-over-year quarterly Cash and Short Term Investments increased by 610.28%
  • Annual Cash and Short Term Investments for 2019 was $22.6 Million (a -10.21% decrease from previous year)
  • Annual Cash and Short Term Investments for 2018 was $25.1 Million (a 1285.45% increase from previous year)
  • Annual Cash and Short Term Investments for 2017 was $1.82 Million (a -67.52% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cash and Short Term Investments of Windtree Therapeutics, Inc.

Most recent Cash and Short Term Investmentsof WINT including historical data for past 10 years.

Interactive Chart of Cash and Short Term Investments of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Cash and Short Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $31.52 $16.8
2019 $22.58 $4.44 $8.66 $15.57 $22.58
2018 $25.15 $0.64 $0.64 $1.85 $25.15
2017 $1.82 $1.75 $2.53 $8.02 $1.82
2016 $5.59 $12.38 $20.33 $29.4 $5.59
2015 $38.72 $46.31 $26.09 $35.58 $38.72
2014 $44.71 $54.92 $65.56 $75.94 $44.71
2013 $86.28 $21.18 $31.25 $26.37 $86.28
2012 $26.89 $36.06 $46.01 $54.8 $26.89
2011 $10.19 $15.41 $21.54 $27.66 $10.19
2010 $10.21 $14.65 $23.32 $24.17 $10.21

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.